Jury Instructions Must Describe All Relevant Objective Indicia of Non-obviousness
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Nefi R. Oliva & Nathan D. Reeves
INLINE PLASTICS CORP V. LACERTA GROUP, LLC
Before Taranto, Chen, and Hughes. Appeal from the United States District Court for the District of Massachusetts.
Summary: Jury instructions must instruct the jury to consider all relevant objective indicia of non-obviousness.
Inline Plastics Corp. (“Inline”) sued Lacerta Group, LLC (“Lacerta”) for infringement of several of its patents relating to tamper-proof containers. At trial, the jury determined that the asserted claims at issue were invalid and not infringed.
Inline appealed, arguing (among other things) that the district court provided erroneous jury instructions. Specifically, Inline argued that the jury instructions had failed to describe and instruct the jury to consider several relevant objective indicia of non-obviousness. For example, the instructions failed to mention the objective indicia of copying, licensing, and industry praise, although Inline had provided evidence of each of them. Instead, the jury instructions only mentioned the objective indicia of commercial success and long-felt need.
The Federal Circuit agreed with Inline and remanded the case for a new trial on invalidity. The court ruled that the jury instructions were improper because they failed to describe all the relevant objective indicia. Furthermore, the Federal Circuit found the error was not harmless because it was clear from the verdict that the jury relied only on obviousness to determine that at least some claims were invalid, and because the prima facie case of obviousness was not too strong for a reasonable jury to find that the objective indicia, taken as a whole, outweighed it.
Editor: Sean Murray
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…